Compare WMK & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | PGEN |
|---|---|---|
| Founded | 1912 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | WMK | PGEN |
|---|---|---|
| Price | $74.37 | $4.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 108.5K | ★ 3.7M |
| Earning Date | 02-24-2026 | 03-18-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ 6.99 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $4,894,832,000.00 | $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $19.05 | ★ N/A |
| Revenue Growth | 2.20 | ★ 59.20 |
| 52 Week Low | $61.53 | $1.11 |
| 52 Week High | $90.23 | $5.23 |
| Indicator | WMK | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 75.74 | 51.56 |
| Support Level | $68.29 | $4.37 |
| Resistance Level | $69.31 | $5.02 |
| Average True Range (ATR) | 1.56 | 0.40 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 94.37 | 47.24 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.